alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
                                                                 EXHIBIT 10.12.1

                    FIRST AMENDEMENT TO EMPLOYMENT AGREEMENT



         This First Amendment to Employment Agreement by and between Pediatrix
Medical Group, Inc., a Florida corporation ("Company") and Karl B. Wagner
("Executive") effective January 1, 1999 (the "Agreement") is made and entered
into as of the 1st day of January, 2003.

         WHEREAS, the parties entered into the Agreement as of the 20th day of
April, 1999;

         WHEREAS, the Agreement set forth certain duties and responsibilities of
both the Company and the Executive as they related to Executive's role as Chief
Financial Officer of Company; and

         WHEREAS, the parties desire to amend such Agreement to clarify and
memorialize certain changes thereto;

         NOW THEREFORE, in consideration of the recitals above and the mutual
covenants and conditions herein, Company and Executive agree that effective
January 1, 2003, this Amendment modifies the referenced Agreement only as
follows:

         1. The text of Section 2.1, Base Salary, shall be deleted in its
entirety and replaced with the following:

                  2.1 BASE SALARY. "Commencing January 1, 2003, the Executive
                  shall receive a base salary at the annual rate of not less
                  than Three Hundred Thousand Dollars ($300,000) (the "Base
                  Salary") during the term of this Agreement, with such Base
                  Salary payable in installments consistent with the Company's
                  normal payroll schedule, subject to required applicable
                  withholding taxes."

         2. The text of Section 2.2 Performance Bonus, shall be deleted in its
entirety and replaced with the following:

                  2.2 PERFORMANCE BONUS. For each calendar year during the
                  Employment Period, the Executive shall be eligible to receive
                  a performance bonus (the "Performance Bonus") in an amount of
                  up to one hundred percent (100%) of the Base Salary, with the
                  actual amount, if any, to be determined at the sole discretion
                  of the Compensation Committee of the Company's Board of
                  Directors. The Company shall pay the Performance Bonus, if
                  any, to the Executive within ninety (90) days after the end of
                  each applicable calendar year.



                                       1
<PAGE>

         Except as amended herein, all other terms and conditions of the
Agreement shall remain unchanged and in full force and effect.


         IN WITNESS WHEREOF, the parties have executed this Amendment 1 as of
the 1st day of January, 2003.



PEDIATRIX MEDICAL GROUP, INC.                        EXECUTIVE:


By: /s/ Roger J. Medel, M.D.                          /s/ Karl B. Wagner
   ------------------------------                    ------------------------
        Roger J. Medel, M.D., M.B.A.                      Karl B. Wagner
        Chief Executive Officer


                                       2
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS WHICH ARE INCLUDED IN
THE REGISTRANT'S FORM 10-Q FOR THE PERIOD ENDED 6/30/00 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK>                         814241
<NAME>                        Formica Corporation
<MULTIPLIER>                                          1,000
<CURRENCY>                                     U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                                    DEC-31-2000
<PERIOD-START>                                       JAN-01-2000
<PERIOD-END>                                         JUN-30-2000
<EXCHANGE-RATE>                                                1
<CASH>                                                    17,600
<SECURITIES>                                                   0
<RECEIVABLES>                                            136,900
<ALLOWANCES>                                               7,300
<INVENTORY>                                              160,500
<CURRENT-ASSETS>                                         350,800
<PP&E>                                                   463,000
<DEPRECIATION>                                            52,600
<TOTAL-ASSETS>                                           941,100
<CURRENT-LIABILITIES>                                    187,300
<BONDS>                                                  459,200
<PREFERRED-MANDATORY>                                          0
<PREFERRED>                                                    0
<COMMON>                                                     100
<OTHER-SE>                                               110,200
<TOTAL-LIABILITY-AND-EQUITY>                             941,100
<SALES>                                                  355,300
<TOTAL-REVENUES>                                         355,300
<CGS>                                                    258,200
<TOTAL-COSTS>                                            260,100
<OTHER-EXPENSES>                                         101,300
<LOSS-PROVISION>                                               0
<INTEREST-EXPENSE>                                        22,100
<INCOME-PRETAX>                                         (28,200)
<INCOME-TAX>                                             (2,900)
<INCOME-CONTINUING>                                     (31,100)
<DISCONTINUED>                                                 0
<EXTRAORDINARY>                                                0
<CHANGES>                                                      0
<NET-INCOME>                                            (31,100)
<EPS-BASIC>                                                    0
<EPS-DILUTED>                                                  0


</TABLE>
§ 74.2307 D&C Red No. 7 ( a ) *Identity and specifications.* The color additive D&C Red No. 7 shall conform in identity and specifications to the requirements of § 74.1307 (a)(1) and (b).
( b ) *Uses and restrictions.* The color additive D&C Red No. 7 may be safely used for coloring cosmetics generally in amounts consistent with current good manufacturing practice.
( c ) *Labeling requirements.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 7 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 57688, Dec. 28, 1982]
##### 



Exhibit 32.2
 
  (1)
    
    The Report fully complies with the requirements of Section 13(a) or 15(d), as
applicable, of the Securities Exchange Act of 1934, as amended; and(2)
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.
 /s/ Blake T. BarnettBlake T. BarnettChief Financial OfficerMarch 13, 2008
 The foregoing certification is being furnished solely to accompany this Report pursuant to 18
U.S.C. §1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, and is not to be incorporated by reference into any filing of the Company,
whether made before or after the date hereof, regardless of any general incorporation language in
such filing.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          AUG-31-1998
<PERIOD-START>                             SEP-01-1997
<PERIOD-END>                               AUG-31-1998
<CASH>                                         117,840
<SECURITIES>                                    11,088
<RECEIVABLES>                                6,424,005
<ALLOWANCES>                                   190,000
<INVENTORY>                                  9,189,973
<CURRENT-ASSETS>                            16,391,425
<PP&E>                                      16,217,627
<DEPRECIATION>                               9,117,371
<TOTAL-ASSETS>                              23,519,946
<CURRENT-LIABILITIES>                        8,334,031
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        53,038
<OTHER-SE>                                  11,745,883
<TOTAL-LIABILITY-AND-EQUITY>                23,519,946
<SALES>                                     50,666,085
<TOTAL-REVENUES>                            50,666,085
<CGS>                                       45,612,279
<TOTAL-COSTS>                               45,612,279
<OTHER-EXPENSES>                              (44,409)
<LOSS-PROVISION>                               190,000
<INTEREST-EXPENSE>                             558,863
<INCOME-PRETAX>                            (1,403,118)
<INCOME-TAX>                                 (318,609)
<INCOME-CONTINUING>                        (1,084,509)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,084,509)
<EPS-PRIMARY>                                    (.20)
<EPS-DILUTED>                                    (.20)
        

</TABLE>
<PAGE>   1
                                                                      EXHIBIT 24


                                POWER OF ATTORNEY

        The director of Washington Banking Company (the "Company"), whose
signature appears below, hereby appoints Michal D. Cann or Karl C. Krieg, III,
or either of them, as his attorney to sign, in his name and behalf and in any
and all capacities stated below, the Company's Form 10-K Annual Report pursuant
to Section 13 of the Securities Exchange Act of 1934, and likewise to sign any
and all amendments and other documents relating thereto as shall be necessary,
such person hereby granting to each such attorney power to act with or without
the other and full power of substitution and revocation, and hereby ratifying
all that any such attorney or his substitute may do by virtue hereof.

        This Power of Attorney has been signed by the following person in the
capacity indicated, on the 18 day of March, 1999.


<TABLE>
<CAPTION>
Signature                                                  Title
---------                                                  -----
<S>                                                        <C>
/s/  Michal D. Cann                                        Director
----------------------------------
Michal D. Cann

/s/  Orlan D. Dean                                         Director
----------------------------------
Orlan D. Dean

/s/  Marlen L. Knutson                                     Director
----------------------------------
Marlen L. Knutson

/s/  Karl C. Krieg, III                                    Director
----------------------------------
Karl C. Krieg, III

/s/  Jay T. Lien                                           Director
----------------------------------
Jay T. Lien

                                                           Director
----------------------------------
Robert C. Olson
</TABLE>

<PAGE>   2

<TABLE>
<S>                                                        <C>
/s/  Anthony B. Pickering                                  Director
----------------------------------
Anthony B. Pickering

/s/  Larry Scodeller                                       Director
----------------------------------
Larry Scodeller

                                                           Director
----------------------------------
Alvin J. Sherman

/s/  Edward J. Wallgren                                    Director
----------------------------------
Edward J. Wallgren
</TABLE>
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10291]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4585]



[[Page 10291]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Alcohol Abuse and Alcoholism; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Alcohol Abuse and 
Alcoholism, Initial Review Group, Epidemiology, Prevention and 
Behavior Research Review Subcommittee.
    Date: July 7-8, 2010.
    Time: 8 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Lorraine Gunzerath, PhD, MBA, Scientific Review 
Officer, National Institute on Alcohol Abuse and Alcoholism, Office 
of Extramural Activities, Extramural Project Review Branch, 5635 
Fishers Lane, Room 2121, Bethesda, MD 20892-9304. 301-443-2369. 
<a href="/cdn-cgi/l/email-protection#da93bdafb4a0bfa8bb9ab7bbb3b6f4b4b3b2f4bdb5ac"><span class="__cf_email__" data-cfemail="4f06283a21352a3d2e0f222e26236121262761282039">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271 
Alcohol Research Career Development Awards for Scientists and 
Clinicians; 93.272, Alcohol National Research Service Awards for 
Research Training; 93.273, Alcohol Research Programs; 93.891, 
Alcohol Research Center Grants; 93.701, ARRA Related Biomedical 
Research and Research Support Awards., National Institutes of 
Health, HHS)

    Dated: February 26, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4585 Filed 3-4-10; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2647 Copper powder. ( a ) *Identity and specifications.* The color additive copper powder shall conform in identity and specifications to the requirements of § 73.1647 (a)(1) and (b).
( b ) *Uses and restrictions.* Copper powder may be safely used in coloring cosmetics generally, including cosmetics intended for use in the area of the eye, in amounts consistent with good manufacturing practice.
( c ) *Labeling.* The color additive and any mixture prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( d ) *Exemption from certification.* Certification of the color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[42 FR 33724, July 1, 1977]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5800 Tracheostomy tube and tube cuff. ( a ) *Identification.* A tracheostomy tube and tube cuff is a device intended to be placed into a surgical opening of the trachea to facilitate ventilation to the lungs. The cuff may be a separate or integral part of the tracheostomy tube and is, when inflated, intended to establish a seal between the tracheal wall and the tracheostomy tube. The cuff is used to prevent the patient's aspiration of substances, such as blood or vomit, or to provide a means for positive-pressure ventilation of the patient. This device is made of either stainless steel or plastic.
( b ) *Classification.* Class II.
[51 FR 40389, Nov. 6, 1986]
UN PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 17

- 1443

WILLIAM JOHN PETERSON , Plaintiff

- Appellant ,

v.
JACK RICHARD PETERSON; BEAUMONT COMPANIES, INC. , Defendants

- Appellees , and
THOMAS DENNIS PETERSON; THOMAS D. PETERSON, LLC , Defendants

.

Appeal from the United States District Court for the Eastern District of Virginia , at Alexandria

. Anthony John Trenga , District Judge. ( 1:17

- cv

- 00038

- AJT

- TCB )

Submitted : September 21, 2017 Decided: October 3, 2017

Before NIEMEYER, SHEDD, and DUNCAN , Circuit Judges.

Affirmed by un published per curiam opinion

.

William John Peterson, Appellant Pro Se. Miriam Rose Epstein, Tania M. L. Saylor, PETERSON SAYLOR, PLC, Fairfax, Virginia, for Appelle es.2 Unpublished opinions are not binding precedent in this circuit.3 PER CURIAM:

William John Peterson appeals the district court’s order granting D efendants’

motion to dismiss Peterson’ s civil action. In its dispositive order, the district court
explained that it granted the motion to dismiss for the reasons expressed at the motion
hearing, but the record does not contain a transcript of that hearing. An appellant has the
burden of including in the rec ord on appeal a transcript of all parts of the proceedings
material to the issues raised on appeal. Fed. R. App. P. 10(b); 4th Cir. R. 10(c). By
failing to produce a transcript of the motion hearing, Peterson has waived review of the
issues on appeal tha t depend upon the transcript to show error. See generally Fed. R.
App. P. 10(b)(2); Keller v. Prince George’s Cty. , 827 F.2d 952, 954 n.1 (4th Cir. 1987).
As no error appears on the record before us, we affirm the district court’s order. We
dispense wit h oral argument because the facts and legal contentions are adequately
presented in the materials before this court and argument would not aid the decisional

process.

AFFIRMED
§ 582.1207 Calcium lactate. ( a ) *Product.* Calcium lactate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Exhibit 13.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of
Title 18, United States Code), each of the undersigned officers of Deutsche Telekom AG (the "Company"), does hereby certify, to such officer's knowledge, that:

The
Annual Report on Form 20-F for the year ended December 31, 2005, of the Company fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of
operations of the Company.

|Dated: March 27, 2006 |  | /s/KAI-UWE RICKEKai-Uwe Ricke
Chairman of the Management Board                                               
|--------------------- |  | -------------------------------------------------------------------------------------------------------------
|                      |  |                                                                                                              
|Dated: March 27, 2006 |  | /s/DR. KARL-GERHARD EICKDr. Karl-Gerhard Eick
Deputy Chairman of the Management Board
Finance and Controlling

---



QuickLinks
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THE  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION   EXTRACTED  FROM  THE
CONSOLIDATED  FINANCIAL  STATEMENTS OF LADISH CO., INC. AS OF AND FOR THE MONTHS
ENDED MARCH 31, 1999 AND IS  QUALIFIED  IN ITS  ENTIRETY  BY  REFERENCE  TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>                                   1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-START>                                 JAN-01-1999
<PERIOD-END>                                   MAR-31-1999
<CASH>                                         1,545
<SECURITIES>                                   0
<RECEIVABLES>                                  29,555
<ALLOWANCES>                                   300
<INVENTORY>                                    45,972
<CURRENT-ASSETS>                               77,274
<PP&E>                                         87,348
<DEPRECIATION>                                 53,931
<TOTAL-ASSETS>                                 178,045
<CURRENT-LIABILITIES>                          40,159
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       142
<OTHER-SE>                                     69,969
<TOTAL-LIABILITY-AND-EQUITY>                   178,045
<SALES>                                        42,756
<TOTAL-REVENUES>                               42,756
<CGS>                                          39,318
<TOTAL-COSTS>                                  1,657
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             161
<INCOME-PRETAX>                                1,729
<INCOME-TAX>                                   260
<INCOME-CONTINUING>                            1,469
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   1,469
<EPS-PRIMARY>                                  0.11
<EPS-DILUTED>                                  0.10
        

</TABLE>
Exhibit 32.2

                          CERTIFICATION PURSUANT TO
                           18 U.S.C. SECTION 1350,
                            AS ADOPTED PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


 In connection with the Quarterly Report of Home Products International, Inc.
 (the  "Company") on  Form 10-Q for  the period ended  September 27, 2003  as
 filed with the Securities and Exchange  Commission on November 11, 2003,  I,
 James E. Winslow, Executive  Vice President and  Chief Financial Officer  of
 the Company,  certify,  pursuant  to 18  U.S.C.  section  1350,  as  adopted
 pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

 (1)  The Report fully complies with the requirements of section 13(a) or
      15(d) of the Securities Exchange Act of 1934; and

 (2)  The information contained in the Report fairly presents, in all
      material respects, the financial condition and results of operations of
      the Company.


 /s/ JAMES E. WINSLOW
 --------------------
 James E. Winslow
 Executive Vice President and Chief Financial Officer
 November 11, 2003


 A signed original of this written statement required by Section 906 has been
 provided to Home Products International, Inc.  and will be retained by  Home
 Products International, Inc.  and furnished to  the Securities and  Exchange
 Commission or its staff upon request.
#### § 1210.18 Scoring.

Scoring of sanitary conditions required by §§ 1210.11, 1210.14 shall be done by an official inspector of the United States or of any State or municipality thereof or of the country in which the dairy farm or plant is located.